- Home
- TBI vs ENTA Comparison
TBI vs ENTA Comparison
Compare TBI & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBI
- ENTA
- Stock Information
- Founded
- TBI 1985
- ENTA 1995
- Country
- TBI United States
- ENTA United States
- Employees
- TBI N/A
- ENTA N/A
- Industry
- TBI Professional Services
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- TBI Consumer Discretionary
- ENTA Health Care
- Exchange
- TBI Nasdaq
- ENTA Nasdaq
- Market Cap
- TBI 169.2M
- ENTA 164.6M
- IPO Year
- TBI 1996
- ENTA 2013
- Fundamental
- Price
- TBI $6.19
- ENTA $7.54
- Analyst Decision
- TBI Buy
- ENTA Strong Buy
- Analyst Count
- TBI 1
- ENTA 5
- Target Price
- TBI $8.00
- ENTA $20.20
- AVG Volume (30 Days)
- TBI 110.3K
- ENTA 168.0K
- Earning Date
- TBI 11-03-2025
- ENTA 08-11-2025
- Dividend Yield
- TBI N/A
- ENTA N/A
- EPS Growth
- TBI N/A
- ENTA N/A
- EPS
- TBI N/A
- ENTA N/A
- Revenue
- TBI $1,534,863,000.00
- ENTA $64,806,000.00
- Revenue This Year
- TBI $2.21
- ENTA N/A
- Revenue Next Year
- TBI $6.18
- ENTA $1.65
- P/E Ratio
- TBI N/A
- ENTA N/A
- Revenue Growth
- TBI N/A
- ENTA N/A
- 52 Week Low
- TBI $3.45
- ENTA $4.09
- 52 Week High
- TBI $9.05
- ENTA $13.37
- Technical
- Relative Strength Index (RSI)
- TBI 53.53
- ENTA 40.89
- Support Level
- TBI $5.41
- ENTA $7.28
- Resistance Level
- TBI $5.96
- ENTA $8.86
- Average True Range (ATR)
- TBI 0.29
- ENTA 0.53
- MACD
- TBI 0.07
- ENTA -0.20
- Stochastic Oscillator
- TBI 64.46
- ENTA 13.76
About TBI TrueBlue Inc.
TrueBlue Inc is a provider of staffing and workforce management solutions. Its reportable segments include PeopleReady offers industrial staffing services. PeopleManagement offers contingent and productivity-based on-site industrial staffing services and PeopleScout offers recruitment process outsourcing, talent advisory services, and managed service provider services. It generates maximum revenue from the PeopleReady segment.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.